Few attempts have been made to examine the feasibility of safely administering low-molecular-weight-heparins (LMWHs) in the presence of concurrent thrombocytopenia. We retrospectively investigated the safety of lowdose LMWH in BMT patients, a population at risk of bleeding. In total, 26 patients received at least one dose of low-dose enoxaparin (ie o1 mg/kg/day) during thrombocytopenia. s.c. enoxaparin 40 mg once daily was given in 85% of the cohort. The mean number of platelet days o55 Â 10 9 and o20 Â 10 9 /l were 16.5 days (95% CI ¼ 8.04-24.96) and 4.14 days (95% CI ¼ 2.35-5.93), respectively. The mean number of low-dose enoxaparin administration days when platelet o55 Â 10 9 and 20 Â 10 9 /l were 9.89 days (95% CI ¼ 3.26-16.53) and 2.25 days (95% CI ¼ 0.57-3.93), respectively. Minor bleeding occurred in four patients (15%) whereas major episodes developed in two patients (8%). The latter two events occurred during the transition between full therapeutic (ie 1.5-2 mg/kg/day) and low-dose enoxaparin close to the onset of thrombocytopenia. The present case series, along with the discussed literature, descriptively suggests that low-dose enoxaparin may be safely administered at a platelet count in the range of 20 and 55 Â 10 9 /l in BMT patients who weigh 455 kg.
bleeding; thrombocytopenia
When given high-dose chemotherapy, hematopoietic stem cell transplantation (HSCT) patients invariably experience severe thrombocytopenia, with platelet counts falling below 50 Â 10 9 /l for 2-3 weeks in autologous HSCT, and longer in allogeneic HSCT transplantation. 1 Platelet engraftment can be impeded by the occurrence post transplant of complications of veno-occlusive disease (VOD) and GVHD in allogeneic HSCT. 2 Indeed, in the presence of GVHD, recovery of platelet count is a slow and gradual process, with 50% of patients remaining thrombocytopenic at day 50. 3 The incidence of major bleeding owing to prolonged thrombocytopenia ranged between 14 and 17% in one series evaluating platelet transfusion threshold in HSCT recipients. 4 Along with the expected thrombocytopenia, HSCT patients demonstrate a high incidence of thromboembolic complications. The etiology of these thrombotic events (TE) is multifactorial, and they may occur before, during, or after transplantation. Prior to transplantation, some patients may have developed TE secondary to: active malignancy, [5] [6] [7] chemotherapy and hormonal treatment for the treatment of adjuvant/metastatic breast cancer, 8 L-asparaginase in ALL, 7 thalidomide in renal cell carcinoma or multiple myeloma 9, 10 all-trans-retinoic acid in acute promyelocytic leukemia, 11 coexistent thrombophilia, 12 continuous infusion GM-CSF use in inferior vena cava apheresis catheters, 13 and indwelling catheters. [14] [15] [16] During transplantation, TE are primarily associated with the use of central venous catheters. 14, 17, 18 Post transplant, VOD of the liver may be partly triggered by a procoagulant state at the endothelial level. 19 Taken together, a clinical predicament arises: how to treat de novo TE patients experiencing concomitant severe thrombocytopenia owing to the administration of high-dose chemotherapy. The continuation of anticoagulation in patients with a history of TE and imminent thrombocytopenia (eg induced by high-dose chemotherapy), is yet another vexing dilemma. Unfortunately, due to the paucity of data regarding this dilemma and the real risk of bleeding, it is not uncommon for practioners to temporarily discontinue anticoagulation during periods of thrombocytopenia. 20 This paper retrospectively investigates the safety of lowdose low-molecular-weight heparins (LMWHs) therapy in thrombocytopenic HSCT patients in both the initiation and continuation of therapy for TE. Building on our initial experience with an autologous HSCT patient reported in 2002, we describe our expanded institutional experience with the LMWH enoxaparin in 26 HSCT patients. 21 
Patients and methods
Between August 2001 and August 2004, all HSCT patients treated at Wayne State University's bone marrow transplantation program, who received LMWHs regardless of the indication, were retrospectively identified using chart review and institutional computerized database. Patients who received at least one s.c. dose of the low-dose (ie o1 mg/kg/day) enoxaparin (Lovenox s , Aventis Pharmaceuticals; Kansas City, MO, USA) during thrombocytopenia were only included. The primary objective of the analysis was to evaluate the safety of administration of lowdose enoxaparin in this patient population at risk for bleeding. Specifically, we sought to determine the incidence of bleeding episodes during thrombocytopenia when lowdose enoxaparin was administered.
Demographic information including age, gender, actual body weight, TE localization, indication and type of HSCT, and preparative regimen was recorded. The number of platelet days o55 Â 10 9 and o20 Â 10 9 /l, the number of platelet transfusions, the number of days low-dose enoxaparin was administered while platelets count was o55 Â 10 9 and o20 Â 10 9 /l, the number of days of lowdose enoxaparin interruptions during thrombocytopenia, and the number of bleeding events were determined for each patient upon occurrence of thrombocytopenia. All patients were followed until platelet count was greater than 100 Â 10 9 /l. For the purpose of this analysis, a platelet transfusion was defined as a single event, independent of the actual number of donor units administered. Thrombocytopenia was defined as platelet count below 55 Â 10 9 /l. A bleeding event was classified as major if it was associated with death, occurred at a critical site (intracranial, intraspinal, intraocular, retroperitoneal, or pericardial area), resulted in a need for a transfusion of at least 2 U of blood, or led to a drop in Hb of at least 2.0 g/dl. 22 Minor bleeding included clinically overt bleeding that did not meet the criteria for a major bleed (including injection-site bruising). 23 Full-dose anticoagulation was defined as 1.5-2 mg/kg/day of s.c. enoxaparin (or equivalent LMWHs doses) given for more than 24 h.
Descriptive analysis was carried out as appropriate to an observational case series. Enoxaparin exposures (ie treatments, or safety evaluations) were regarded as statistically independent observations (as well as patients) for the purpose of descriptive analysis. The study was approved by the Human Investigation Committee at Wayne State University.
Results

Study population
From August 2001 to August 2004, 42 HSCT patients had documented TE. Of these 42 patients, 26 patients received at least one dose of enoxaparin during thrombocytopenia as identified by chart review and institutional computerized database. Overall, 30 TEs were documented (four patients had two TEs in different sites). The majority of TEs were upper extremity deep venous thrombosis (11/30 ¼ 36%) of which all were catheter-related episodes. Six patients (23%) had documented TE during the peritransplant period (ie from conditioning regimen to engraftment): five upper extremity deep venous thrombosis and one atrial thrombus. They were all catheter-related TEs.
Our institutional protocol called for platelet transfusion at 10 Â 10 9 /l for all patients, and 50 Â 10 9 /l for patients contemplating invasive procedures. In patients experiencing bleeds, platelets were usually transfused to maintain a platelet count above 420 Â 10 9 /l. The base-line demographics of these 26 patients are shown in Table 1 . In total, 19 patients (73%) received autologous HSCT with one patient undergoing tandem autologous HSCT (total autologous HSCTs ¼ 20). The most common conditioning regimens were: melphalan (n ¼ 9), Cy/TBI (n ¼ 3), and BEAM (n ¼ 3). Two patients received enoxaparin twice during two successive thrombocytopenic periods, tandem autologous HSCT for relapsed metastatic testicular cancer, and cyclophosphamide priming and autologous HSCT respectively. Each exposure was analyzed as a separate safety evaluation, thereby accounting for 28 safety evaluations.
Prior to the occurrence of thrombocytopenia, 54% (14/26) of patients were receiving full therapeutic anticoagulation. The majority of patients (54%) continued full anticoagulation following platelet engraftment. Lowdose enoxaparin was 40 mg in 85% (22/26) of the cohort. Three patients received 60 mg once daily (wt ¼ 80, 88 and 113 kg) and one testicular cancer patient 40 mg twice daily on two occasions for his tandem HSCT (wt ¼ 176 kg). Table 2 illustrates the findings of the 28 safety evaluations performed. When normalized to the individual patient weight, low-dose enoxaparin distribution during thrombocytopenia was found to have a mean of 0.5 mg/kg/day (95% CI: 0.46-0.55) and a median of 0.4915 mg/kg/day (range 0.341-0.754). Of note, in 15 safety evaluations (53%), the platelet count did not fall below 20 Â 10 9 /l.
Enoxaparin during thrombocytopenia
Bleeding episode (28 safety evaluations)
In 28 safety evaluations, minor bleeding occurred in four instances (14%) whereas major episodes developed in two patients (7%). Table 3 contains a detailed description of these events. The first major hemorrhage was a retroperitoneal bleed that developed in an autologous HSCT patient during the transition from enoxaparin 2.35 mg/kg/day to 40 mg once daily (B0.6 mg/kg/day) when platelet count dropped from 83 Â 10 9 to 51 Â 10 9 /l. The bleed resolved within 10 days with supportive care and the patient uneventfully resumed enoxaparin treatment at B1.2 mg/kg/day. A second retroperitoneal hemorrhage occurred when enoxaparin was switched from 40 mg once daily (0.46 mg/kg/day) to 1.15 mg/kg/day at a platelet count of 52 Â 10 9 /l in a nonmyeloablative HSCT on D þ 25. This patient had concurrent acute renal failure with a serum creatinine of 2 mg/dl on the day of the event and 3 mg/dl 4 days before the event. The patient clinically deteriorated and died on D þ 62 secondary to multiple organ failure.
All minor bleeds (n ¼ 4) were without adverse sequelea and low-dose enoxaparin was resumed within days of interruption, despite thrombocytopenia. None of the bleeds (major or minor) were age related. In some instances, clinicians elected not to give the LMWH when the platelet count fell below 20 Â 10 9 /l (Table 2) . During thrombocytopenia, antifactor Xa activity levels were reported in five patients. The median 4-h post-dose antifactor Xa activity level was 0.28 IU/ml (range: 0.04-0.4 IU/ml) (mean ¼ 0.268 IU/ml; 95% CI ¼ 0.214-0.322).
Discussion
Two large randomized trials examining the efficacy of LMWHs anticoagulation in cancer patients in prevention of DVT, and the prolongation of survival were recently published. 22, 24 In both trials, cancer patients with baseline thrombocytopenia (ie platelet count o50 Â 10 9 /l) were excluded. The management of either full-dose anticoagulation 22 or low-dose LMWHs (dalteparin 5000 U once daily 24 and 2500 U once daily 25 ) during periods of thrombocytopenia were not mentioned in most publications. Another LMWH, Nadroparin, was studied in the prevention of central venous catheter (CVC)-associated thrombosis in HSCT recipients. Neither bleeding events nor information on the degree of thrombocytopenia and dose interruptions were reported in this retrospective trial. 26 Similarly, the use of very-low-dose warfarin (ie 1-mg daily) for the prevention of CVC-TE in thrombocytopenic cancer patients was either not fully described 27, 28 or discontinued when platelets were below o50 Â 10 9 /l. 29 In clinical practice, practitioners are inclined to empirically withhold antithrombotic therapy until platelet count is above 50 Â 10 9 /l for fear of bleeding. To illustrate this, in a prospective follow-up study of 181 Number of patients on full-dose enoxaparin prior to thrombocytopenia (%)
(54%)
DVT ¼ deep venous thrombosis; UE ¼ upper extremity; LE ¼ lower extremity. a Two patients received enoxaparin twice during two successive thrombocytopenic periods: tandem autologous HSCT for relapsed metastatic testicular cancer in the first case, and following cyclophosphamide priming and autologous HSCT in the other. b Coronary artery disease (n ¼ 1), VOD prevention (n ¼ 1), atrial fibrillation (n ¼ 1), deep venous thrombosis prophylaxis (n ¼ 1), catheter-related atrial thrombus (n ¼ 1). /l). The practice of withholding antithrombotics is not without unfavorable repercussions. In one report, the authors speculated that the 75% (191/255) interruptions rate in patients receiving very-low-dose-warfarin interruptions (ie 1 mg daily) may have contributed to the observed lack of effect on the reduction of symptomatic DVT. 31 Our report represents the largest descriptive HSCT patient data set primarily looking at a priori LMWH safety during thrombocytopenia (Table 4) . Simon et al compared s.c. enoxaparin 30 mg twice daily for the prevention of VOD in 106 HSCT patients with unfractionated heparin and unfractionated heparin/prostaglandins. The LMWH was initiated within 24 h of conditioning regimen and continued until day of discharge or day 28 post HSCT. 32 Aside from demonstrating efficacy in the prevention of VOD, the hemorrhagic events with enoxaparin were 4% (vs 22% unfractionated heparin/prostaglandin vs 11% unfractionated heparin; P40.1). 32 No specific details were given on either platelet count at which bleeding occurred or treatment interruptions. Drakos et al 33 treated five thrombocytopenic patients undergoing HSCT for catheterassociated upper extremity VTE with s.c. enoxaparin 40 mg twice daily for 2 weeks, followed by a 2-month treatment with once-daily enoxaparin 40 mg. The baseline platelets count (for four patients) and steady-state anti-Xa concentrations ranged between 15-22 Â 10 9 /l and 0.17-0.4 IU/ml, respectively. The fifth patient baseline platelet count was 126 Â 10 9 /l; however, thrombocytopenia occurred a few days after LMWH therapy. The administration of enoxaparin was not associated with generalized bleeding phenomena or hemorrhages at sites of the LMWHs injection. 33 In a randomized placebo-controlled pilot trial, once-daily s.c. 40-mg enoxaparin was evaluated for the prevention of hepatic VOD. 34 In total, 28 patients received low-dose enoxaparin for a mean of 20 days. The LMWH arm was administered in the presence of severe thrombocytopenia (mean duration o20 Â 10 9 /l: 9 days). There were no differences in major or minor bleeding events between the experimental arm and placebo (Po0.05). Mean number and duration of severe hemor- Table 4 Literature evaluating anticoagulant use in thrombocytopenic cancer patients (in chronological order of publications) 34 More recently, a Canadian prospective singlearm phase II trial examined the use of the LMWH dalteparin for the prevention of VOD in 40 allogeneic and autologous HSCT. Dalteparin was given s.c. as 2500 U daily until day of discharge or day 30 post HSCT. 35 In total, 24 patients (60%) developed a minor bleeding. Three patients (7.5%) had a major bleed defined as bleeding episode requiring transfusions of 1-2 of packed RBCs/ episode in a 24-h period. One case of vaginal bleeding occurred at a platelet count of 7 Â 10 /l in HSCT patients. All of the documented major hemorrhagic events (7%) occurred within this range while on full-dose anticoagulation, albeit the presence of renal dysfunction may have heightened the risk.
Major bleeding with full anticoagulant LMWH doses has been reported up to occur in 5 and 12.5% of noncancer and cancer patients, respectively. 30, 44 We have encountered an 7% incidence of major bleeding (one fatal), and 14% minor bleeding in our HSCT cohort. A close look at the major bleeds identified two potential contributors: acute renal failure coupled with platelet count 51 Â 10 9 /l and 1.15 mg/kg/dose and 2.25 mg/kg/day within 24 h of thrombocytopenia. Severe alcoholism, underlying morbidity, age 460 years, female gender, renal impairment (even mild to moderate), history of bleeding diathesis, and receiving concomitant medications that can affect hemostasis were all identified as risk factors for retroperitoneal bleeding. [45] [46] [47] [48] [49] In general, this serious adverse event has been reported with treatment and prophylactic doses of enoxaparin, with highest risk in patients receiving doses approaching 1 mg/ kg q12h. 45, 46 On average, it occurs as early as within 4 days of enoxaparin therapy. [45] [46] [47] [48] [49] To avoid bleeding in the presence of moderate to severe renal impairment (creatinine clearance o30 ml/min), monitoring LMWHs use with antifactor Xa activity is recommended. 50 A cautionary note: our results cannot be extrapolated to patients who weigh below o55 kg. In the underweight patient, low-dose anticoagulation may yield antifactor Xa levels close to the therapeutic range, putting the patients at a risk of bleeding. Indeed, several authors suggested that underweight patients, that is, o40 kg, should have periodic monitoring of antifactor Xa activity during prophylactic (goal peak antifactor Xa level of 0.1-0.2 IU/ml) or therapeutic treatment (goal peak antifactor Xa level of 0.4-1.1 IU/ml) with LMWHs. 51 In one report, patients with a BSA o2 m 2 had a 7.3-fold higher risk of bleeding on LMWHs. 52 Retrospective studies suffer from drawbacks such as reliance on chart reviews that may be subject to erroneous documentation or missing 'real-time' information. Another limitation of our case series is the discontinuous use of enoxaparin made it difficult to firmly establish cause and effect. Consequently, we were not able to detect a correlation between individualized dosing expressed as mg/ kg/dose (or, alternatively, as a target peak antifactor Xa activity level) and the rate of bleeding, at a given platelet count. For these same reasons, we are also unable to calculate the time to bleeding and its relation with platelet count (and nadir) and the administered LMWHs doses. Noteworthy, bleeding does not depend only on platelet count and the administration of LWMHs but also on patients' factors such as the presence of fever, infection, presence of invasive procedures, impairment in platelet function, and higher platelet consumption states. [53] [54] [55] These factors may explain why bleeding occurs even if platelet count is 450 Â 10 9 /l. 55 Only a randomized prospective design can robustly take into account these patient's conditions.
Our single institution case series, coupled with the presented literature, suggests that low-dose LMWHs, chiefly enoxaparin, may be safe in HSCT patients with platelet count between 20 Â 10 9 and 55 Â 10 9 /l and who weigh 455 kg. Furthermore, it suggests against using fulldose anticoagulation when platelet count is o90 Â 10 9 /l, especially in patients with compromised renal function. Owing to the descriptive nature of the case series, these findings need to be confirmed in randomized controlled trials.
